• June 3-6, 2024
  • San Diego Convention Center, California



Humanetics Corporation

Monday, June 03, 2024
Multiple Therapeutics
Company Presentation Theater 3
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Humanetics entered the field of radiation modulators through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). AFRRI's mission is the discovery and early development of drugs that can protect warfighters from the harmful effects of radiation. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from the Department of Defense to Humanetics. In the ensuing years, the Company has progressed this program into clinical stage with a primary focus on improving the treatment outcomes for patients receiving radiation treatment of solid tumors. Humanetics has three open INDs for BIO 300. We have active clinical programs focused on medical countermeasures, solid tumor radiotherapy and in COVID-19. The Company has recently received a $20 million grant from the DoD for BIO 300.
Humanetics Corporation
Company Website: https://www.humaneticscorp.com/
Lead Product in Development: BIO 300
Number Of Unlicensed Products (For Which You Are Seeking Partners): 1

Company HQ City


Company HQ State


Company HQ Country

United States

CEO/Top Company Official

Ronald Zenk

Development Phase of Primary Product

Phase II
Primary Speaker
Ronald Zenk, MBA
Chief Executive Officer
Humanetics Corporation
Back to Session List


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.